NewLink Genetics Corporation Company Profile (NASDAQ:NLNK)

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NLNK
  • CUSIP: 65151110
  • Web: www.newlinkgenetics.com
Capitalization:
  • Market Cap: $321.8 million
  • Outstanding Shares: 29,421,000
Average Prices:
  • 50 Day Moving Avg: $8.77
  • 200 Day Moving Avg: $12.66
  • 52 Week Range: $5.90 - $25.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.43
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $41.18 million
  • Price / Sales: 7.85
  • Book Value: $3.50 per share
  • Price / Book: 3.14
Profitability:
  • EBIDTA: ($55,580,000.00)
  • Net Margins: -161.94%
  • Return on Equity: -55.03%
  • Return on Assets: -41.24%
Debt:
  • Current Ratio: 4.95%
  • Quick Ratio: 4.95%
Misc:
  • Average Volume: 1.97 million shs.
  • Beta: 1.27
  • Short Ratio: 10.35
 

Frequently Asked Questions for NewLink Genetics Corporation (NASDAQ:NLNK)

What is NewLink Genetics Corporation's stock symbol?

NewLink Genetics Corporation trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics Corporation's earnings last quarter?

NewLink Genetics Corporation (NASDAQ:NLNK) released its earnings results on Friday, July, 28th. The company reported ($0.57) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.21. The firm earned $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. View NewLink Genetics Corporation's Earnings History.

When will NewLink Genetics Corporation make its next earnings announcement?

NewLink Genetics Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for NewLink Genetics Corporation.

Where is NewLink Genetics Corporation's stock going? Where will NewLink Genetics Corporation's stock price be in 2017?

5 analysts have issued 1 year price targets for NewLink Genetics Corporation's stock. Their forecasts range from $22.00 to $30.00. On average, they anticipate NewLink Genetics Corporation's share price to reach $26.60 in the next twelve months. View Analyst Ratings for NewLink Genetics Corporation.

What are analysts saying about NewLink Genetics Corporation stock?

Here are some recent quotes from research analysts about NewLink Genetics Corporation stock:

  • 1. Cantor Fitzgerald analysts commented, "Incremental Data Points in the Right Direction. Updated data from the Phase I/II trial in advanced melanoma (excluding ocular melanoma), showed improving complete responses (CRs) to 20% vs. 12% reported at six months. The overall response rate (ORR) and disease control rate (DCR) were stable at 61% and 80%, respectively, vs. 59% and 80% at six months." (9/8/2017)
  • 2. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (7/29/2017)
  • 3. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
  • 4. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Who are some of NewLink Genetics Corporation's key competitors?

Who are NewLink Genetics Corporation's key executives?

NewLink Genetics Corporation's management team includes the folowing people:

  • Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
  • John Bell Henneman III, Chief Financial Officer, Secretary
  • Brian Wiley, Chief Commercial Officer
  • Thomas A. Raffin M.D., Lead Independent Director
  • Paolo Pucci, Director
  • Paul R. Edick, Independent Director
  • Ernest J. Talarico III, Independent Director
  • Lota S. Zoth CPA, Independent Director

Who owns NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include INTEGRATED CORE STRATEGIES (US) LLC (5.80%), Vanguard Group Inc. (3.17%), FMR LLC (2.44%), Columbus Circle Investors (2.02%), State Street Corp (1.33%) and Northern Trust Corp (1.02%). Company insiders that own NewLink Genetics Corporation stock include Brian Wiley, Carl W Langren, Charles J Jr Link and John B Henneman III. View Institutional Ownership Trends for NewLink Genetics Corporation.

Who sold NewLink Genetics Corporation stock? Who is selling NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, Bank of New York Mellon Corp, Ameriprise Financial Inc., Vanguard Group Inc., Tiverton Asset Management LLC, Schwab Charles Investment Management Inc. and GSA Capital Partners LLP. View Insider Buying and Selling for NewLink Genetics Corporation.

Who bought NewLink Genetics Corporation stock? Who is buying NewLink Genetics Corporation stock?

NewLink Genetics Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Quantitative Investment Management LLC, Candriam Luxembourg S.C.A., PDT Partners LLC, Tudor Investment Corp ET AL, Dimensional Fund Advisors LP, Alliancebernstein L.P. and Bank of Montreal Can. View Insider Buying and Selling for NewLink Genetics Corporation.

How do I buy NewLink Genetics Corporation stock?

Shares of NewLink Genetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics Corporation's stock price today?

One share of NewLink Genetics Corporation stock can currently be purchased for approximately $10.99.


MarketBeat Community Rating for NewLink Genetics Corporation (NASDAQ NLNK)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NewLink Genetics Corporation (NASDAQ:NLNK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.60 (142.04% upside)

Analysts' Ratings History for NewLink Genetics Corporation (NASDAQ:NLNK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Stifel NicolausBoost Price TargetBuy -> Buy$14.00 -> $29.00HighView Rating Details
9/8/2017Cantor FitzgeraldReiterated RatingBuy$26.00HighView Rating Details
9/8/2017Robert W. BairdUpgradeNeutral -> Outperform$8.00 -> $22.00MediumView Rating Details
9/8/2017Jefferies Group LLCUpgradeHold -> Buy$7.00 -> $26.00HighView Rating Details
3/30/2017SunTrust Banks, Inc.UpgradeHold -> Buy$12.00 -> $30.00HighView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for NewLink Genetics Corporation (NASDAQ:NLNK)
Earnings by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Earnings History by Quarter for NewLink Genetics Corporation (NASDAQ NLNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.76)N/AView Earnings Details
7/28/2017Q2 2017($0.78)($0.57)$2.65 million$10.37 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.46)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)ViewN/AView Earnings Details
11/11/2013Q3($0.33)($0.32)ViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.23 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)
2017 EPS Consensus Estimate: ($3.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20172($0.82)($0.75)($0.79)
Q4 20171($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NewLink Genetics Corporation (NASDAQ:NLNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NewLink Genetics Corporation (NASDAQ:NLNK)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 54.78%
Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Insider Trades by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.05View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.15View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.50View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NewLink Genetics Corporation (NASDAQ:NLNK)
Latest Headlines for NewLink Genetics Corporation (NASDAQ:NLNK)
Source:
DateHeadline
feeds.benzinga.com logoBenzinga's Option Alert Recap From September 22
feeds.benzinga.com - September 22 at 5:49 PM
fool.com logo3 Small-Cap Biotech Stocks to Buy This Fall
www.fool.com - September 21 at 8:36 AM
finance.yahoo.com logoETFs with exposure to NewLink Genetics Corp. : September 19, 2017
finance.yahoo.com - September 20 at 6:54 AM
finance.yahoo.com logoNewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 3:59 AM
americanbankingnews.com logo Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Post Quarterly Sales of $2.38 Million
www.americanbankingnews.com - September 17 at 8:08 AM
americanbankingnews.com logo-$0.80 Earnings Per Share Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - September 15 at 2:26 PM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - September 14 at 12:20 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 13 at 4:44 PM
finance.yahoo.com logoAnalyst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
finance.yahoo.com - September 12 at 6:03 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Price Target Raised to $29.00 at Stifel Nicolaus
www.americanbankingnews.com - September 11 at 8:10 AM
benzinga.com logoNewLink Genetics Follows Through On Thursday's Rally After Upgrade
www.benzinga.com - September 10 at 3:03 AM
seekingalpha.com logoNewLink Genetics Corporation (NLNK) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 10 at 3:03 AM
finance.yahoo.com logoOptions Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock
finance.yahoo.com - September 10 at 3:03 AM
finance.yahoo.com logoWhy NewLink Genetics Corporation (NLNK) Could Be A Buy
finance.yahoo.com - September 10 at 3:03 AM
nasdaq.com logoMid-Afternoon Market Update: Crude Oil Down Over 3%; Zumiez Shares Gain Following Strong Results - Nasdaq
www.nasdaq.com - September 9 at 6:43 AM
nasdaq.com logoHealth Care Sector Update for 09/08/2017: NLNK, KURA, TNDM, MRK - Nasdaq
www.nasdaq.com - September 9 at 6:43 AM
nasdaq.com logoOptions Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock - Nasdaq
www.nasdaq.com - September 9 at 6:43 AM
seekingalpha.com logoNewLink Genetics Data Catches Wall Street By Surprise - Seeking Alpha
seekingalpha.com - September 9 at 6:43 AM
finance.yahoo.com logoWhy NewLink Genetics, Zumiez, and Everest Re Group Jumped Today
finance.yahoo.com - September 9 at 6:43 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Given "Overweight" Rating at Cantor Fitzgerald
www.americanbankingnews.com - September 9 at 12:32 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Lifted to "Buy" at Jefferies Group LLC
www.americanbankingnews.com - September 8 at 11:14 PM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Stock Rating Upgraded by Robert W. Baird
www.americanbankingnews.com - September 8 at 3:42 PM
fool.com logoWhy NewLink Genetics Is Soaring 37.5% Higher Today
www.fool.com - September 8 at 1:22 PM
fool.com logoHere's Why NewLink Genetics Is Vaulting 45% Higher Today - Motley Fool
www.fool.com - September 8 at 6:23 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - September 7 at 11:58 PM
fool.com logoHere's Why NewLink Genetics Is Vaulting 45% Higher Today
www.fool.com - September 7 at 2:01 PM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - September 2 at 8:50 PM
seekingalpha.com logoAnd Then There Was One: NewLink Genetics Refocuses Efforts On Indoximod, Its Remaining, Undervalued Late-Stage ... - Seeking Alpha
seekingalpha.com - September 2 at 6:46 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Expected to Post Quarterly Sales of $2.38 Million
www.americanbankingnews.com - August 30 at 11:46 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Given a $7.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - August 26 at 8:16 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 19 at 2:48 PM
americanbankingnews.com logo Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Announce Quarterly Sales of $2.38 Million
www.americanbankingnews.com - August 11 at 10:26 AM
americanbankingnews.com logoResearch Analysts Set Expectations for NewLink Genetics Corporation's FY2017 Earnings (NASDAQ:NLNK)
www.americanbankingnews.com - August 3 at 9:50 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for NewLink Genetics Corporation Reduced by Analyst (NASDAQ:NLNK)
www.americanbankingnews.com - August 2 at 7:02 AM
seekingalpha.com logoNewLink Genetics' (NLNK) CEO Charles Link, Jr. on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 30 at 1:31 AM
globenewswire.com logoNewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program - GlobeNewswire (press release)
globenewswire.com - July 29 at 8:30 PM
americanbankingnews.com logoNewLink Genetics Corporation (NASDAQ:NLNK) Announces Quarterly Earnings Results
www.americanbankingnews.com - July 29 at 4:08 PM
americanbankingnews.com logoNewLink Genetics Corporation (NASDAQ:NLNK) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 29 at 9:04 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Given a $26.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - July 29 at 7:59 AM
finance.yahoo.com logoNewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
finance.yahoo.com - July 29 at 5:26 AM
finance.yahoo.com logoNewLink reports 2Q loss
finance.yahoo.com - July 29 at 5:26 AM
streetinsider.com logoNewLink Genetics (NLNK) Announces First Patient Dosed in Phase ... - StreetInsider.com
www.streetinsider.com - July 28 at 6:08 AM
finance.yahoo.com logoNewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
finance.yahoo.com - July 28 at 6:08 AM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) to Release Earnings on Friday
www.americanbankingnews.com - July 27 at 1:47 PM
americanbankingnews.com logoNewLink Genetics Corporation (NLNK) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 25 at 3:06 PM
americanbankingnews.com logoZacks: Brokerages Expect NewLink Genetics Corporation (NASDAQ:NLNK) Will Announce Quarterly Sales of $2.65 Million
www.americanbankingnews.com - July 22 at 10:23 AM
americanbankingnews.com logo-$0.78 Earnings Per Share Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - July 20 at 12:41 PM
americanbankingnews.com logoNewLink Genetics Corporation (NASDAQ:NLNK) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - July 15 at 2:56 PM
finance.yahoo.com logoETFs with exposure to NewLink Genetics Corp. : July 12, 2017
finance.yahoo.com - July 13 at 7:20 AM
prnewswire.com logoBiotech Stock Performance Review -- NewLink Genetics, Ocera Therapeutics, Ocular Therapeutix, and Omeros - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:21 AM

Social

Chart

NewLink Genetics Corporation (NLNK) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff